Short Interest in Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) Decreases By 74.5%

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 429,000 shares, a decline of 74.5% from the October 31st total of 1,680,000 shares. Based on an average daily volume of 2,950,000 shares, the short-interest ratio is currently 0.1 days. Currently, 2.0% of the company’s stock are sold short.

Cardio Diagnostics Stock Down 3.2 %

Shares of NASDAQ:CDIO traded down $0.01 during mid-day trading on Thursday, reaching $0.30. 1,413,718 shares of the stock were exchanged, compared to its average volume of 1,319,485. Cardio Diagnostics has a one year low of $0.19 and a one year high of $3.56. The stock’s 50 day simple moving average is $0.26 and its 200-day simple moving average is $0.43.

Wall Street Analyst Weigh In

Separately, Benchmark reiterated a “speculative buy” rating and issued a $2.00 price target on shares of Cardio Diagnostics in a report on Tuesday, August 27th.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease.